Is Oruka Therapeutics, Inc. (ORKA) overvalued? · $4.27B cap
Oruka Therapeutics, Inc. (ORKA) is a biotechnology company listed on NASDAQ.
This page asks whether Oruka Therapeutics, Inc. (ORKA) looks expensive on cached numbers — not a short thesis.
Latest reported ORKA revenue for 2024-06-30 was $0. Net income was -$22.2M. ORKA currently screens at market cap $4.27B.
ORKA currently screens at market cap $4.27B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ORKA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ORKA stock page for the full model, not this heading.
Not investment advice.